RANIBIZUMAB VS. VERTEPORFIN PHOTODYNAMIC THERAPY FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION- COST EFFECTIVENESS STUDY IN PORTUGAL
Author(s)
Montóia B1, Guerreiro T1, Viriato D2
1Novartis Farma – Produtos Farmaceuticos S.A., Porto Salvo, Portugal, 2Novartis Farma – Produtos Farmacêuticos S.A., Porto Salvo, Portugal
OBJECTIVES: Choroidal neovascularization (CNV) is the most common vision-threatening complication associated with pathologic myopia (PM), a progressive condition characterized by axial elongation and degenerative changes in the posterior segment of the eye. This study aimed to evaluate the cost effectiveness of ranibizumab compared with verteporfin photodynamic therapy (vPDT) in patients with visual impairment due to myopic CNV in the Portuguese setting. METHODS: A Markov model was developed with health states defined by best-corrected visual acuity and a 3-month cycle length. The study has taken under National Health Service perspective and included societal perspective in an alternative scenario, considering a lifetime time horizon. The study was based on 2013 prices considering future costs and health outcomes to be discounted at 5.0% per annum. The baseline characteristics considered were retrieved from the phase III RADIANCE study (Ranibizumab and vPDT Evaluation in Myopic CNV), and VIP study (Verteporfin in Photodynamic Therapy). Extensive sensitivity analyses tested the robustness of the model. RESULTS: From NHS perspective, the lifetime cost of treating myopic CNV with ranibizumab was €8,241.73 whereas vPDT was associated with a total cost of €10,732.81. In the alternative scenario, from societal perspective those costs amount to €8,815.22 and €11.333,83, for ranibizumab and vPDT, respectively. Ranibizumab treatment produced higher cumulative quality-adjusted life-years (QALYs; 8.95) than vPDT (8.70). Ranibizumab treatment was therefore dominant in both scenarios, with greater health gains and lower overall costs than vPDT. In the probabilistic sensitivity analysis, ranibizumab had a 100% probability of being cost effective compared with vPDT, at an informal willingness-to-pay threshold of €30.000/QALY. CONCLUSIONS: This cost effectiveness study indicates that the therapy with ranibizumab is dominant over vPDT for the treatment of visual impairment due to CNV secondary to pathologic myopia from both NHS and society perspectives.
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PSS28
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Sensory System Disorders